T Alexander Russell-Smith (Alexander Russell-Smith, T A Russell-Smith)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 15

Top Topics

Palliative Care

Ejection Fraction

Cross Sectional

Top Venues

Journal of comparative effectiveness research

PharmacoEconomics - open

This page only lists publications with an associated author ORCID identifier.

Publications

T Alexander Russell-Smith, Louise B Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah S Webb, Stephanie Dorman, Richa Shah
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Journal of comparative effectiveness research 13 (2) (2023)
T Alexander Russell-Smith, Louise B Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah S Webb, Stephanie Dorman, Richa Shah
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Journal of comparative effectiveness research 13 (2) (2023)
Rebecca Crawford, Slaven Sikirica, Ross Morrison, Joseph Christopher Cappelleri, T Alexander Russell-Smith, Richa Shah, Helen Chadwick, Lynda Doward
The Patient Experience of Acute Lymphoblastic Leukemia and Its Treatment: Social Media Review. JMIR cancer 9 (2023)
Rebecca Crawford, Slaven Sikirica, Ross Morrison, Joseph Christopher Cappelleri, T Alexander Russell-Smith, Richa Shah, Helen Chadwick, Lynda Doward
Correction: The Patient Experience of Acute Lymphoblastic Leukemia and Its Treatment: Social Media Review. JMIR cancer 9 (2023)
T Alexander Russell-Smith, Louise B Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah S Webb, Stephanie Dorman, Richa Shah
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Journal of comparative effectiveness research (2023)
T Alexander Russell-Smith, Louise B Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah S Webb, Stephanie Dorman, Richa Shah
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Journal of comparative effectiveness research 13 (2) (2023)
Rebecca Crawford, Slaven Sikirica, Ross Morrison, Joseph Christopher Cappelleri, T Alexander Russell-Smith, Richa Shah, Helen Chadwick, Lynda Doward
The Patient Experience of Acute Lymphoblastic Leukemia and Its Treatment: Social Media Review. JMIR cancer 9 (2023)
T Alexander Russell-Smith, Louise B Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah S Webb, Stephanie Dorman, Richa Shah
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Journal of comparative effectiveness research 13 (2) (2023)
Rebecca Crawford, Slaven Sikirica, Ross Morrison, Joseph Christopher Cappelleri, T Alexander Russell-Smith, Richa Shah, Helen Chadwick, Lynda Doward
The Patient Experience of Acute Lymphoblastic Leukemia and Its Treatment: Social Media Review. JMIR cancer 9 (2023)
T Alexander Russell-Smith, Louise B Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah S Webb, Stephanie Dorman, Richa Shah
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Journal of comparative effectiveness research (2023)
Rebecca Crawford, Slaven Sikirica, Ross Morrison, Joseph Christopher Cappelleri, T Alexander Russell-Smith, Richa Shah, Helen Chadwick, Lynda Doward
Correction: The Patient Experience of Acute Lymphoblastic Leukemia and Its Treatment: Social Media Review. JMIR cancer 9 (2023)
T Alexander Russell-Smith, Louise B Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah S Webb, Stephanie Dorman, Richa Shah
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Journal of comparative effectiveness research 13 (2) (2023)
Rebecca Crawford, Slaven Sikirica, Ross Morrison, Joseph Christopher Cappelleri, T Alexander Russell-Smith, Richa Shah, Helen Chadwick, Lynda Doward
The Patient Experience of Acute Lymphoblastic Leukemia and Its Treatment: Social Media Review. JMIR cancer 9 (2023)
I van Oostrum, T Alexander Russell-Smith, M Jakobsson, J Torup Østby, B Heeg
Cost-Effectiveness of Inotuzumab Ozogamicin Compared to Standard of Care Chemotherapy for Treating Relapsed or Refractory Acute Lymphoblastic Leukaemia Patients in Norway and Sweden. PharmacoEconomics - open (2021)
T Alexander Russell-Smith, James Brockbank, Carla Mamolo, Christopher Knight
Cost Effectiveness of Gemtuzumab Ozogamicin in the First-Line Treatment of Acute Myeloid Leukaemia in the UK. PharmacoEconomics - open 5 (4) (2021)